Delving into the Latest Updates on arGEN-X BV with Synapse

Overview

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Endocrinology and Metabolic Disease

Fc Fragment

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	3
Endocrinology and Metabolic Disease	3
Neoplasms	2
Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Infectious Diseases	1

Top 5 Drug Type	Count

Fc Fragment	2
Monoclonal antibody	2

Top 5 Target	Count

IL-6(Interleukin-6)	1
APOC3(Apolipoprotein C-III)	1
FcRn x Hyaluronic acid	1
FcRn(IgG receptor FcRn large subunit p51)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 2 Clinical

Phase 3 Clinical

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Efgartigimod ( FcRn )	Myasthenia Gravis More	Approved
Efgartigimod/Hyaluronidase ( FcRn x Hyaluronic acid )	Pemphigoid, Bullous More	Phase 3 Clinical
Gerilimzumab ( IL-6 )	Rheumatoid Arthritis More	Phase 2
ARGX-116 ( APOC3 )	Hyperlipidemias More	Preclinical